Vyleesi® product results: 14% growth in prescriptions dispensed over prior quarter – 6 consecutive quarters of double digit growth.
Click here to learn more ›

October 2019

Palatin Presents On Pl8177 Oral Colon Delivery Formulation For Ulcerative Colitis At The 7Th CPC Symposium On Peptide Therapeutics

Press Releases / By

CRANBURY, N.J., Oct. 17, 2019 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) announced that John Dodd, Ph.D., Palatin’s Vice President of Pre-Clinical Development, provided a presentation on Palatin’s oral colon delivery formulation, PL8177 in development for the treatment of ulcerative colitis, at the 7th CPC Symposium on Peptide Therapeutics in Hangzhou, China. Dr. Dodd …

Palatin Presents On Pl8177 Oral Colon Delivery Formulation For Ulcerative Colitis At The 7Th CPC Symposium On Peptide Therapeutics Read More »

Vyleesi™ Phase 3 Data To Be Presented At The 13th European Society Of Gynecology Congress

Press Releases / By

Oct 16, 2019, 07:00 ET CRANBURY, N.J., Oct. 16, 2019 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) announced today that data from two pivotal, double-blind placebo-controlled Phase 3 trials (RECONNECT) and the Exit Survey/Interview data on Vyleesi™ (bremelanotide injection) for hypoactive sexual desire disorder (HSDD) will be presented at the 13th European Society of …

Vyleesi™ Phase 3 Data To Be Presented At The 13th European Society Of Gynecology Congress Read More »

Scroll to Top